Analysis
Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy
Eve A. Roberts, Matthew Herder and Aidan Hollis
CMAJ April 07, 2015 187 (6) 422-425; DOI: https://doi.org/10.1503/cmaj.140308
Eve A. Roberts
Division of Gastroenterology, Hepatology and Nutrition (Roberts), The Hospital for Sick Children; Departments of Paediatrics, Medicine, and Pharmacology and Toxicology (Roberts), University of Toronto, Toronto, Ont.; Health Law Institute (Herder), Faculties of Medicine and Law, Dalhousie University, Halifax, NS; Department of Economics (Hollis), University of Calgary, Alta.
MD MAMatthew Herder
Division of Gastroenterology, Hepatology and Nutrition (Roberts), The Hospital for Sick Children; Departments of Paediatrics, Medicine, and Pharmacology and Toxicology (Roberts), University of Toronto, Toronto, Ont.; Health Law Institute (Herder), Faculties of Medicine and Law, Dalhousie University, Halifax, NS; Department of Economics (Hollis), University of Calgary, Alta.
LLM JSMAidan Hollis
Division of Gastroenterology, Hepatology and Nutrition (Roberts), The Hospital for Sick Children; Departments of Paediatrics, Medicine, and Pharmacology and Toxicology (Roberts), University of Toronto, Toronto, Ont.; Health Law Institute (Herder), Faculties of Medicine and Law, Dalhousie University, Halifax, NS; Department of Economics (Hollis), University of Calgary, Alta.
PhD
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy
Eve A. Roberts, Matthew Herder, Aidan Hollis
CMAJ Apr 2015, 187 (6) 422-425; DOI: 10.1503/cmaj.140308
Jump to section
Related Articles
Cited By...
- No citing articles found.